05.03.2021

HIV-Associated Cancers and Related Diseases

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Dr. Yarchoan reports having Cooperative Research and Development Agreements (CRADAs) with Celgene, Hoffmann–La Roche, Bayer, and Merck, having a pending patent (PCT/US2016/039245) on Methods for the Treatment of Kaposi’s Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers, and holding a patent (9,474,793) on vaccines and methods for the prevention and treatment of drug-resistant HIV-1 and hepatitis B virus, two patents (6,509,321 and 6,423,308) on treatment of Kaposi’s sarcoma with interleukin-12, and a patent (4,707,443) on soluble interleukin-2 receptor as a disease indicator and a method of assaying the same; and Dr. Uldrick, having CRADAs with Celgene, Hoffmann–La Roche, Bayer, and Merck and a pending patent (PCT/US2016/039245) on Methods for the Treatment of Kaposi’s Sarcoma or KSHV-Induced Lymphoma Using Immunomodulatory Compounds, and Uses of Biomarkers; all issued and pending patents of Drs. Yarchoan and Uldrick are assigned to the U.S. Government, with a portion of the royalties going to employee-inventors under the Federal Technology Transfer Act of 1986 (P.L. 99-502). No other potential conflict of interest relevant to this article was reported.

We thank Dr. H. Irene Hall for providing an earlier version of Figure 1A.

Spread the love

Leave a Reply

Your email address will not be published. Required fields are marked *